



## **Avalanche Biotechnologies to Present at the 26th Annual Piper Jaffray Healthcare Conference**

November 26, 2014

MENLO PARK, Calif., Nov. 26, 2014 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that Thomas W. Chalberg, Jr., Ph.D., Founder and Chief Executive Officer, will present at the 26<sup>th</sup> Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 1:30 pm EST in New York, NY.

### **About Avalanche Biotechnologies, Inc.**

Avalanche is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Avalanche's lead product, AVA-101, is currently under development in a Phase 2a trial for wet AMD. Avalanche's Ocular BioFactory™ platform technology is a proprietary adeno-associated virus (AAV)-based gene therapy discovery and development technology optimized for ophthalmology that utilizes a directed evolution approach to generate novel drug candidates. For more information please visit [www.avalanchebiotech.com](http://www.avalanchebiotech.com).

#### CONTACT: Investor Contact:

Chris Erdman  
MacDougall Biomedical Communications  
(781) 235-3060  
[cerdman@macbiocom.com](mailto:cerdman@macbiocom.com)

#### Media Contact:

Kathy Vincent  
(310) 403-8951  
[kathy@kathyvincent.com](mailto:kathy@kathyvincent.com)

[Avalanche Biotechnologies Logo](#)

Avalanche Biotechnologies, Inc.